<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Michael Gibson, MS, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramon Corbalan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Alexander, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most cases of acute myocardial infarction (MI) are caused by coronary artery plaque rupture with subsequent thrombus formation. When thrombosis leads to total occlusion of blood flow, acute ST-elevation MI (STEMI) is often the clinical outcome. Patients with acute STEMI should receive coronary reperfusion therapy with either primary percutaneous coronary intervention (PCI) or fibrinolysis. Reperfusion improves clinical outcomes in nearly all groups who present within 12 hours of symptom onset.</p><p>The decision to initiate reperfusion therapy should be based on the clinical presentation and electrocardiographic changes. Supporting evidence such as troponin elevation or imaging abnormalities is not required except in doubtful situations such as possible posterior wall MI or preexisting left bundle branch block.</p><p>For most patients with acute STEMI, we prefer primary PCI rather than fibrinolysis. However, fibrinolytic therapy should be used if timely primary PCI is not available. (See  <a class="medical medical_review" href="/d/html/115790.html" rel="external">"Mechanisms of acute coronary syndromes related to atherosclerosis"</a> and  <a class="medical medical_review" href="/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p>This topic will discuss the use of fibrinolytic therapy in patients with STEMI. The discussion of failed fibrinolysis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H1576777607"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>After a decision has been made to treat with fibrinolytic therapy rather than primary percutaneous coronary intervention (PCI) (see  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>), we use the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Start parenteral anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>  (<a class="graphic graphic_algorithm graphicRef139386" href="/d/graphic/139386.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Dosing and duration of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who arrive initially at a hospital or in whom the diagnosis is made in an ambulance, fibrinolytic therapy should be initiated within 10 minutes of electrocardiographic diagnosis of STEMI. (See <a class="local">'Timing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We prefer fibrin-specific agents over streptokinase, and we prefer the third-generation agents <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> and <a class="drug drug_general" data-topicid="9857" href="/d/drug information/9857.html" rel="external">reteplase</a> over <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>  (<a class="graphic graphic_table graphicRef56744" href="/d/graphic/56744.html" rel="external">table 1</a>) based on their generally favorable benefit-to-risk profile and ease of use. Dosing is provided in a table  (<a class="graphic graphic_table graphicRef56744" href="/d/graphic/56744.html" rel="external">table 1</a>). (See <a class="local">'Choice of agent'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer orally (if possible): <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, and a statin. We give 162 to 325 mg of uncoated aspirin and 300 mg of clopidogrel (75 mg in patients ≥75 years of age). (See <a class="local">'Concomitant therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We refer many patients for early diagnostic angiography and PCI after fibrinolysis, particularly those at high risk for a recurrent cardiovascular event. We consult with a cardiologist soon after initiation of fibrinolysis. (See <a class="local">'Angiography after fibrinolysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients deemed to be at lower risk and for whom transfer to a PCI center may be difficult, risk stratification with stress testing is reasonable. Patients with a positive stress test should then be referred for coronary angiography.</p><p></p><p class="headingAnchor" id="H2016035764"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>Fibrinolytic (ie, thrombolytic) therapy, when administered within the first several hours after symptom onset, is capable of reestablishing antegrade coronary artery blood flow in nearly 75 percent of patients with STEMI. The restoration of myocardial blood flow is key to improving cardiovascular outcomes. The benefit of fibrinolytic therapy declines rapidly as the time from onset of symptoms to therapy increases beyond three hours. After 12 hours, the risk may exceed the benefit. (See <a class="local">'Timing'</a> below.)</p><p>All fibrinolytic agents, compared with placebo, reduce mortality in acute STEMI. The magnitude of reduction in risk of death in randomized trials is generally between 15 and 30 percent. The trials supporting this conclusion are described in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p>Streptokinase was the first intravenous agent in which a mortality benefit, when compared with placebo, was demonstrated [<a href="#rid1">1</a>]. Subsequently, <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>, <a class="drug drug_general" data-topicid="9857" href="/d/drug information/9857.html" rel="external">reteplase</a>, and <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> (by comparison with alteplase) were shown to have similar or better clinical outcomes compared with streptokinase [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2210607848"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>All STEMI patients who cannot receive primary percutaneous coronary intervention in a timely manner should be considered immediately for fibrinolytic therapy. (See  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p>Fibrinolytic therapy should <strong>not</strong> await the availability of results of cardiac biomarkers if the diagnosis is reasonably certain. (See  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Cardiac biomarkers and other laboratory testing'</a>.)</p><p>Patients with chest pain suggestive of acute myocardial ischemia who present up to 12 (and possibly up to 24) hours after symptom onset are candidates for fibrinolytic therapy if the following electrocardiographic evidence is present:</p><p class="bulletIndent1"><span class="glyph">●</span>New ST elevation at the J point in two anatomically contiguous leads using the following diagnostic thresholds: ≥0.1 mV (1 mm) in all leads other than V2 to V3, where the following diagnostic thresholds apply: ≥0.2 mV (2 mm) in men ≥40 years, ≥0.25 mV (2.5 mm) in men &lt;40 years, or ≥0.15 mV (1.5 mm) in women [<a href="#rid4">4,5</a>].</p><p></p><p>Patients with typical and persistent symptoms in the presence of a new or presumably new left bundle branch block or a true posterior MI are also considered eligible. (See  <a class="medical medical_review" href="/d/html/2095.html" rel="external">"Electrocardiogram in the diagnosis of myocardial ischemia and infarction"</a> and  <a class="medical medical_review" href="/d/html/2104.html" rel="external">"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm"</a> and  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H1119337127"><span class="h1">USE IN SPECIFIC PATIENT GROUPS</span><span class="headingEndMark"> — </span>Although concerns have been raised about the use of fibrinolytic therapy in each of the following patient groups, we believe that the benefit outweighs the risk in most.</p><p class="headingAnchor" id="H3616381787"><span class="h2">Older patients</span><span class="headingEndMark"> — </span>We do not believe that age, in the absence of other risk factors of adverse outcomes with fibrinolytic therapy, is an absolute contraindication.</p><p>The mortality associated with STEMI treated with fibrinolytic therapy increases with advancing patient age, and fibrinolytic therapy improves outcomes compared with placebo in older individuals [<a href="#rid6">6</a>]. The frequency of left ventricular free-wall rupture (see  <a class="medical medical_review" href="/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications", section on 'Rupture of the left ventricular free wall'</a>) or major bleeding, and in particular intracranial hemorrhage, is higher in older patients treated with fibrinolytic therapy.</p><p>Similar to our approach to the use of fibrinolytic therapy in the general population, we prefer fibrin-specific agents over streptokinase, and we prefer <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> over other fibrin-specific agents  (<a class="graphic graphic_table graphicRef56744" href="/d/graphic/56744.html" rel="external">table 1</a>). (See <a class="local">'Our approach'</a> above.)</p><p>For older patients who receive <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> as part of a pharmacoinvasive approach (eg, fibrinolysis with bolus tenecteplase followed by rescue or elective percutaneous coronary intervention [PCI] within 24 hours), an alternate dosing was evaluated in the STREAM trial [<a href="#rid7">7</a>] (see  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>). We do not use this dosing in our practices.</p><p>In STREAM, which randomly assigned patients to either a pharmacoinvasive approach or primary PCI, a protocol adjustment was made after enrollment that reduced the <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> dose to 50 percent in patients 75 years of age or older due to an excess of intracranial hemorrhage (ICH) in that age group in the early enrollees. This dose adjustment decreased the incidence of ICH. The overall trial results showed no significant difference between the two reperfusion strategies. This approach of reducing the dose of tenecteplase to 50 percent in older patients undergoing a pharmacoinvasive strategy is unproven and is being studied directly in the ongoing STREAM-2 trial (ClinicalTrials.gov identifier: NCT02777580). (See  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy", section on 'Short duration of symptoms'</a>.)</p><p class="headingAnchor" id="H2855995717"><span class="h2">Cardiogenic shock</span><span class="headingEndMark"> — </span>In patients with cardiogenic shock, we have a strong preference for primary PCI rather than fibrinolytic therapy. However, for patients who cannot receive timely primary PCI, fibrinolysis followed by PCI (even if there is a delay of up to 24 hours) is the preferred strategy. This is especially the case if the patient presents early (&lt;3 hours) after symptom onset. (See  <a class="medical medical_review" href="/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2042173083"><span class="h2">Menstruating women</span><span class="headingEndMark"> — </span>For menstruating women with acute STEMI, we use fibrinolytic therapy if that would have otherwise been our preference. Some practitioners are concerned about the use of fibrinolytic agents in menstruating women. In one small study, there was no significant increase in severe bleeding compared with nonmenstruating women [<a href="#rid8">8</a>]. There was a significant increase in moderate bleeding that was offset by the benefits of fibrinolytic therapy.</p><p class="headingAnchor" id="H1171216482"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Absolute contraindications to fibrinolytic therapy include prior intracranial hemorrhage (ICH), known structural cerebral vascular lesion, known malignant intracranial neoplasm, ischemic stroke within three months, suspected aortic dissection, active bleeding or bleeding diathesis, or significant closed-head or facial trauma within three months  (<a class="graphic graphic_table graphicRef68784" href="/d/graphic/68784.html" rel="external">table 2</a>).</p><p>Important relative contraindications include  (<a class="graphic graphic_table graphicRef68784" href="/d/graphic/68784.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Poorly controlled or chronic sustained hypertension (ie, systolic blood pressure &gt;180 mmHg) [<a href="#rid9">9,10</a>]. This can be mitigated somewhat if the blood pressure is reduced prior to fibrinolytic administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic stroke more than three months previously. Most patients with a history of stroke were excluded from clinical fibrinolytic trials and, in clinical practice, are less likely to receive a fibrinolytic agent. Data evaluating such patients are extremely limited. In a review of 115 patients with acute MI who had a prior nonhemorrhagic cerebrovascular event, 29 were given fibrinolytic therapy [<a href="#rid11">11</a>]. None of the 29 patients had an intracranial bleed, and these patients had a lower one-year mortality than 46 patients with a prior stroke who did not receive a fibrinolytic agent (18 versus 33 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dementia or other intracranial pathology (except as above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Traumatic or prolonged cardiopulmonary resuscitation (&gt;10 minutes) or major surgery (within &lt;3 weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent (within two to four weeks) internal bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncompressible vascular puncture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For streptokinase, prior exposure (more than five days previously and up to one year) or prior allergic reaction to these agents. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active peptic ulcer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current use of anticoagulants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of ICH. It has been suggested that fibrinolysis has a greater potential for harm than benefit if the risk of ICH exceeds 4 percent [<a href="#rid12">12</a>]. (See <a class="local">'Stroke'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraocular hemorrhage from fibrinolytic therapy in patients with diabetes mellitus is rare, and diabetic retinopathy should not be considered a contraindication to fibrinolytic therapy in acute MI [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H69239839"><span class="h1">INITIATION OF THERAPY</span><span class="headingEndMark"> — </span>For patients with STEMI in whom fibrinolysis is chosen as the reperfusion strategy (ie, when primary percutaneous coronary intervention is not available), treatment should be given as soon as possible after the diagnosis. (See <a class="local">'Indications'</a> above.)</p><p>Administration of fibrinolytic therapy before hospital arrival (eg, in an ambulance) is an established practice in many geographies. The rationale, training, treatment protocols, and quality assurance programs needed to ensure a safe and effective prehospital fibrinolysis program are presented separately. (See  <a class="medical medical_review" href="/d/html/13865.html" rel="external">"Performance of prehospital fibrinolysis"</a>.)</p><p class="headingAnchor" id="H69239847"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The time from first medical contact, whether it be in an ambulance capable of delivering fibrinolytic therapy or a hospital emergency department, to drug administration (ie, door-to-needle time) should be less than 30 minutes [<a href="#rid4">4,5,15</a>]. Ideally, fibrinolytic therapy should be delivered within 10 minutes of STEMI confirmation on the electrocardiogram. (See  <a class="medical medical_review" href="/d/html/13865.html" rel="external">"Performance of prehospital fibrinolysis"</a> and  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p>As the length of time between a patient's presentation and delivery of fibrinolytic therapy (ie, door-to-needle time) increases, the benefit from therapy decreases. The survival benefit is greatest when fibrinolytic agents are administered within the first four hours after onset of symptoms [<a href="#rid2">2,16-23</a>], and particularly within the first 70 minutes  (<a class="graphic graphic_figure graphicRef53374" href="/d/graphic/53374.html" rel="external">figure 1</a>) [<a href="#rid18">18,19</a>]. Although this conclusion is largely derived from clinical trials, similar findings have been noted in the community, as demonstrated in the second National Registry of Myocardial Infarction [<a href="#rid21">21</a>]. Early therapy also has the greatest impact on infarct size and left ventricular ejection fraction [<a href="#rid19">19,20,23,24</a>].</p><p>A mortality benefit is less likely with fibrinolytic therapy at 13 to 18 hours. A meta-analysis from the Fibrinolytic Therapy Trialists' Collaborative Group found that the absolute mortality benefit from fibrinolytic therapy at five weeks was 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [<a href="#rid17">17</a>].</p><p>However, there may be a benefit in patients presenting 12 hours after symptom onset and possibly up to 24 hours if the patient has ongoing or stuttering chest pain [<a href="#rid25">25</a>]. Although most myocardial necrosis occurs early (ie, within the first 90 to 180 minutes), the advantages of late reperfusion are presumably related to the presence of a patent infarct-related vessel, leading to improved ventricular healing, reduced infarct expansion, and greater electrical stability.</p><p class="headingAnchor" id="H69239859"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>We prefer fibrin-specific agents over streptokinase, and we prefer the third-generation agents (eg, <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> and <a class="drug drug_general" data-topicid="9857" href="/d/drug information/9857.html" rel="external">reteplase</a>) over <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> based on their generally favorable benefit-to-risk profile and ease of use. The following conclusions regarding available agents have been reached from randomized trials and support our choice of tenecteplase:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">Alteplase</a> improves survival compared with streptokinase (streptokinase is not available in the United States or Canada). (See  <a class="medical medical_review" href="/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9857" href="/d/drug information/9857.html" rel="external">Reteplase</a> is comparable to <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> but is easier to use (it is given as two intravenous boluses, 30 minutes apart) [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">Tenecteplase</a> has comparable efficacy to <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> but has a lower rate of noncerebral bleeding events and is easier to use [<a href="#rid28">28</a>]. It is given as a single bolus and is therefore easier to administer than alteplase, which requires a bolus and then two separate drips. Under- or overdosing are possible with tenecteplase when weight has to be estimated, such as in some emergency situations.</p><p></p><p class="headingAnchor" id="H72323700"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Dosing is available in a table  (<a class="graphic graphic_table graphicRef56744" href="/d/graphic/56744.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H69243493"><span class="h1">CONCOMITANT THERAPIES</span><span class="headingEndMark"> — </span>All STEMI patients receiving fibrinolytic therapy should receive the following therapies as soon as possible after the diagnosis is made.</p><p class="headingAnchor" id="H615821468"><span class="h2">Anticoagulant therapy</span><span class="headingEndMark"> — </span>We treat all STEMI patients receiving fibrinolytic therapy with an anticoagulant. It should be started as soon as a decision to treat with fibrinolytic therapy is made. We choose either <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> for patients, including those who may receive PCI after fibrinolysis  (<a class="graphic graphic_algorithm graphicRef139386" href="/d/graphic/139386.html" rel="external">algorithm 1</a>). A detailed discussion of anticoagulant therapy in STEMI patients who receive fibrinolytic therapy, including the dosing regimens, is found elsewhere. (See  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Fibrinolytic therapy with or without planned PCI'</a>.)</p><p class="headingAnchor" id="H615821501"><span class="h2">Antiplatelet therapy</span><span class="headingEndMark"> — </span>We give nonenteric-coated <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (loading dose of 162 to 325 mg) as soon as possible after the diagnosis has been made.</p><p>Once fibrinolysis is chosen as the reperfusion strategy, we give <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> as a 300 mg loading dose in those ≤75 years of age and a 75 mg loading dose in those &gt;75 years. Transition to a more potent P2Y<sub>12</sub> inhibitor may be appropriate at the time of discharge. (See  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving fibrinolytic therapy'</a>.)</p><p class="headingAnchor" id="H615821507"><span class="h2">Statins</span><span class="headingEndMark"> — </span>For all patients with an acute coronary syndrome not on treatment with a statin, we initiate high-intensity statin therapy (80 mg of <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> or 20 to 40 mg of <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> daily) regardless of the baseline low density lipoprotein-cholesterol level. We start therapy as soon as possible after the diagnosis. (See  <a class="medical medical_review" href="/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Our approach to in-hospital therapy'</a>.)</p><p class="headingAnchor" id="H615821554"><span class="h2">Beta blocker</span><span class="headingEndMark"> — </span>For all patients with acute MI, we recommend initiation of oral beta blockers within the first 24 hours, as long as no contraindications are present. However, early initiation of intravenous beta blocker in the emergency department should be avoided in most patients and in particular those with cardiogenic shock. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p class="headingAnchor" id="H69243077"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Bleeding is the primary complication of fibrinolytic therapy, and hemorrhagic stroke is the greatest concern. Clinically important bleeding modestly reduces the total benefit associated with fibrinolytic therapy. (See  <a class="medical medical_review" href="/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H69243084"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>GUSTO-I, the largest trial of fibrinolytic therapy (eg, streptokinase or <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>), found a 1.8 percent incidence of severe bleeding [<a href="#rid29">29</a>]. The incidence of moderate bleeding, defined by the need for transfusion but without hemodynamic compromise or need for an intervention, was 11.4 percent. Bleeding was most often procedure related, occurring with coronary artery bypass graft surgery in 3.6 percent and at the groin site of a percutaneous coronary intervention in 2 percent. As the use of the radial artery for access has increased, the risk of significant procedure-related bleeding has decreased. (See  <a class="medical medical_review" href="/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management", section on 'Radial versus femoral approach'</a>.)</p><p>The most common site for spontaneous bleeding is the gastrointestinal tract (1.8 percent) [<a href="#rid29">29</a>]. The risk of moderate or severe bleeding appears to be greater in women than in men (odds ratio 1.43) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H69243091"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>The risks of stroke and intracranial hemorrhage (ICH) were 1.2 and 0.7 percent in a non-trial community registry of 12,739 patients [<a href="#rid31">31</a>]. In GUSTO-I, the majority of strokes (95 percent) occurred within five days of therapy [<a href="#rid9">9,32</a>]. The incidence was somewhat higher with <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>.</p><p>Strokes associated with fibrinolysis are also associated with very high rates of mortality and morbidity. In GUSTO-I, the stroke was fatal in 41 percent and produced moderate or severe disability in 31 percent [<a href="#rid9">9</a>]. Similar findings were noted in the (United States) National Registry of Myocardial Infarction 2 [<a href="#rid33">33</a>].</p><p>Risk factors for stroke have been identified from analysis of patients enrolled in randomized trials [<a href="#rid9">9,10,31,33,34</a>]. In GUSTO-I, patients with a previous transient ischemic attack or stroke were at particularly high risk (5.5 and 6.9 percent, respectively) [<a href="#rid9">9</a>]. In the STREAM trial, there was a high incidence of ICH in patients &gt;75 years of age. This risk was reduced after the dose of <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> was reduced by 50 percent in patients 75 years of age or older [<a href="#rid7">7</a>].</p><p>Independent predictors of ICH included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥75 years</p><p class="bulletIndent1"><span class="glyph">●</span>Being from a Black population</p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure ≥160 mmHg</p><p class="bulletIndent1"><span class="glyph">●</span>Weight ≤65 kg for women or ≤80 kg for men</p><p class="bulletIndent1"><span class="glyph">●</span>International normalized ratio &gt;4 or prothrombin time &gt;24 seconds</p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> (versus other fibrinolytic agents)</p><p></p><p>ICH should be suspected in any patient who develops sudden neurological deterioration, a decline in level of consciousness, new headache, nausea and vomiting, or a sudden rise in blood pressure after fibrinolytic therapy, especially within the first 24 hours of treatment. The management of such patients is similar to that for patients with ICH of any cause. (See  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a>.)</p><p>The central steps in the early management of suspected ICH are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinolytic, antiplatelet, and anticoagulant therapies should be discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An emergent noncontrast head computed tomography scan or magnetic resonance imaging scan should be arranged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A neurology and/or neurosurgery consultation should be obtained. A hematology consultation may also be of value.</p><p></p><p>This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16134.html" rel="external">"Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use", section on 'Management of symptomatic intracerebral hemorrhage'</a>.)</p><p class="headingAnchor" id="H69241007"><span class="h1">ANGIOGRAPHY AFTER FIBRINOLYSIS</span><span class="headingEndMark"> — </span>For most STEMI patients, and particularly those at high risk, we suggest early referral for diagnostic angiography and percutaneous coronary intervention (PCI) compared with a strategy of medical therapy, based on evidence of better outcomes with the former. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/53.html" rel="external">"Percutaneous coronary intervention after fibrinolysis for acute ST-elevation myocardial infarction", section on 'Pharmacoinvasive strategy'</a>.)</p><p>For the patient with evidence that reperfusion has been unsuccessful (ie, failed fibrinolysis), we suggest immediate angiography with intent to perform rescue PCI. Primary failure of fibrinolysis is often manifested clinically by persistent or worsening chest pain (particularly if associated with other symptoms such as dyspnea and diaphoresis), persistent or worsening ST-segment elevation, and/or hemodynamic instability or heart failure. However, these clinical factors are not sufficiently predictive in all patients. As a result, in the absence of clear indications of reperfusion, the clinician must maintain a high index of suspicion for primary failure. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"</a>.)</p><p>Successful reperfusion is generally associated with significant improvement in ischemic symptoms, resolution of at least &gt;50 percent ST elevation on the electrocardiogram, hemodynamic stability, improvement in left ventricular function, and the absence of heart failure. For the patient who has responded to fibrinolytic therapy, an important issue is the role of subsequent coronary angiography and revascularization. We suggest diagnostic coronary angiography and possible PCI, generally within 3 to 24 hours, for all patients who receive fibrinolytic therapy. (See  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p class="headingAnchor" id="H69236566"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Guidelines for the use of fibrinolytic therapy in patients with STEMI have been issued by the American College of Cardiology Foundation/American Heart Association in 2013 [<a href="#rid4">4,5</a>] and the European Society of Cardiology in 2017 [<a href="#rid15">15,35</a>]. Our recommendations are generally in accord with those from these organizations.</p><p class="headingAnchor" id="H1405870598"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for most patients with acute ST-elevation myocardial infarction (STEMI). When timely primary PCI is not available, early fibrinolysis should be carried out. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1">We make the following recommendations for the use of fibrinolytic therapy in patients with acute STEMI:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presentation within 12 hours of symptom onset</strong> – For patients within 12 hours of STEMI onset who have no absolute contraindications to fibrinolytic therapy and for whom reperfusion with primary PCI cannot be performed within the recommended time, we recommend fibrinolytic therapy as opposed to no reperfusion therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Initiation of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presentation between 12 to 24 hours of symptoms onset</strong> – For symptomatic patients who present after 12 (but before 24) hours of symptom onset and when PCI is not readily available, we suggest fibrinolytic therapy as opposed to no fibrinolytic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Goal for administration</strong> – Irrespective of whether fibrinolytic therapy is given prehospital or in the hospital (emergency department), it should be started within 30 minutes after the diagnosis of STEMI is made. (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of agent</strong> – We recommend a fibrin-specific agent instead of streptokinase (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). </p><p></p><p class="bulletIndent2">We suggest <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> or <a class="drug drug_general" data-topicid="9857" href="/d/drug information/9857.html" rel="external">reteplase</a> instead of <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Dosing is available in a table  (<a class="graphic graphic_table graphicRef56744" href="/d/graphic/56744.html" rel="external">table 1</a>). (See <a class="local">'Choice of agent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transfer for PCI</strong> – After fibrinolysis, early transfer to a center that can perform PCI may be indicated. (See <a class="local">'Angiography after fibrinolysis'</a> above.)</p><p></p><p class="headingAnchor" id="H110380703"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas Levin, MD, who contributed to previous versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.</a></li><li><a class="nounderline abstract_t">GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673.</a></li><li><a class="nounderline abstract_t">Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001; 286:442.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.</a></li><li><a class="nounderline abstract_t">White HD. Thrombolytic therapy in the elderly. Lancet 2000; 356:2028.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368:1379.</a></li><li><a class="nounderline abstract_t">Karnash SL, Granger CB, White HD, et al. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol 1995; 26:1651.</a></li><li><a class="nounderline abstract_t">Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.</a></li><li><a class="nounderline abstract_t">Aylward PE, Wilcox RG, Horgan JH, et al. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Ann Intern Med 1996; 125:891.</a></li><li><a class="nounderline abstract_t">Tanne D, Gottlieb S, Caspi A, et al. Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: the Israeli Thrombolytic National Survey. Arch Intern Med 1998; 158:601.</a></li><li><a class="nounderline abstract_t">Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7.</a></li><li><a class="nounderline abstract_t">Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:1606.</a></li><li><a class="nounderline abstract_t">Ward H, Yudkin JS. Thrombolysis in patients with diabetes. BMJ 1995; 310:3.</a></li><li><a class="nounderline abstract_t">Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.</a></li><li><a class="nounderline abstract_t">Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995; 25:10S.</a></li><li><a class="nounderline abstract_t">Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.</a></li><li><a class="nounderline abstract_t">Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.</a></li><li><a class="nounderline abstract_t">Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.</a></li><li><a class="nounderline abstract_t">Chareonthaitawee P, Gibbons RJ, Roberts RS, et al. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation). Heart 2000; 84:142.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, Mooradd M, Gurwitz JH, et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). Am J Cardiol 1998; 82:259.</a></li><li><a class="nounderline abstract_t">Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27:1646.</a></li><li><a class="nounderline abstract_t">Gibson CM, Murphy SA, Kirtane AJ, et al. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:980.</a></li><li><a class="nounderline abstract_t">Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 1998; 31:1246.</a></li><li><a class="nounderline abstract_t">Steinberg JS, Hochman JS, Morgan CD, et al. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. Circulation 1994; 90:746.</a></li><li><a class="nounderline abstract_t">Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:1118.</a></li><li><a class="nounderline abstract_t">Topol EJ, Ohman EM, Armstrong PW, et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation 2000; 102:1761.</a></li><li><a class="nounderline abstract_t">Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.</a></li><li><a class="nounderline abstract_t">Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95:2508.</a></li><li><a class="nounderline abstract_t">Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341:226.</a></li><li><a class="nounderline abstract_t">Huynh T, Cox JL, Massel D, et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J 2004; 148:86.</a></li><li><a class="nounderline abstract_t">Mahaffey KW, Granger CB, Sloan MA, et al. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation 1998; 97:757.</a></li><li><a class="nounderline abstract_t">Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129:597.</a></li><li><a class="nounderline abstract_t">Barron HV, Rundle AC, Gore JM, et al. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2. Am J Cardiol 2000; 85:294.</a></li><li><a class="nounderline abstract_t">Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119.</a></li></ol></div><div id="topicVersionRevision">Topic 55 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2868337" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8204123" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11466123" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bolus fibrinolytic therapy in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247303" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247304" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145486" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thrombolytic therapy in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473396" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594099" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586246" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8967669" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521224" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: the Israeli Thrombolytic National Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1598117" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385883" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7827552" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thrombolysis in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922416" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7775708" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7905143" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355383" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908248" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708650" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636549" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337207" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581715" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Time to therapy and salvage in myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044943" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9340503" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A comparison of reteplase with alteplase for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023929" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475182" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9184581" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413734" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215796" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498539" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9786806" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078295" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886621" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
